Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling

Farnesoid‐x‐receptor (FXR) agonists, currently trialed in patients with non‐alcoholic steatosis (NAFLD), worsen the pro‐atherogenic lipid profile and might require a comedication with statin. Here we report that mice feed a high fat/high cholesterol diet (HFD) are protected from developing a pro‐ath...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The FASEB journal 2022-01, Vol.36 (1), p.e22060-n/a
Hauptverfasser:	Marchianò, Silvia, Biagioli, Michele, Roselli, Rosalinda, Zampella, Angela, Di Giorgio, Cristina, Bordoni, Martina, Bellini, Rachele, Morretta, Elva, Monti, Maria Chiara, Distrutti, Eleonora, Fiorucci, Stefano
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Atorvastatin - pharmacology Bacteria - metabolism bile acids Bile Acids and Salts - metabolism cardiovascular diseases Cholesterol 7-alpha-Hydroxylase - metabolism Cholesterol, Dietary - adverse effects Cholesterol, Dietary - pharmacology Fatty Liver - chemically induced Fatty Liver - drug therapy Fatty Liver - metabolism Fatty Liver - microbiology FXR Gastrointestinal Microbiome - drug effects GPBAR1 intestinal microbiota Liver - metabolism Male Mice Receptors, Cytoplasmic and Nuclear - metabolism Receptors, G-Protein-Coupled - metabolism Signal Transduction - drug effects statins Steroid 12-alpha-Hydroxylase - metabolism Vascular Diseases - chemically induced Vascular Diseases - drug therapy Vascular Diseases - metabolism Vascular Diseases - microbiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!